AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
Keep up to date on AgNovos events and related news
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
AgNovos Healthcare Announces Corporate Renaming as AgNovos Bioscience
AgNovos Healthcare is pleased to participate in this year’s British Orthopaedic Association Congress (BOA) from September 20-23 in Birmingham, England.
It is with great pleasure that AgNovos Healthcare announces the recipients of this year’s ESCEO-AgNovos Young Investigator Award presented at World Congress on Osteoporosis in March 2022.
AgNovos Healthcare is pleased to announce the completion of enrollment for its CONFIRM clinical study.